Expression of immune checkpoint molecules in endometrial carcinoma

Experimental and Therapeutic Medicine

Volumn 10, Issue 5, 2015, Pages 1947-1952

  Liu, Jia ^a   Liu, Yuling ^a   Wang, Wuliang ^a   Wang, Chenyang ^a   Che, Yanhong ^b  

^a ZHENGZHOU UNIVERSITY   (China)

^b People's Hospital of Zhengzhou   (China)

Author keywords

Endometrial carcinoma; Immune checkpoint; Immunosuppressant

Indexed keywords

GALECTIN 1; GALECTIN 3; INDOLEAMINE 2,3 DIOXYGENASE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; ENDOMETRIUM CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY INFILTRATE; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; METASTASIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SCORING SYSTEM; TUMOR BIOPSY; UPREGULATION;

EID: 84942243642     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2714     Document Type: Article

References (41)

1. Nguyen TT, Hachisuga T, Urabe R, Kurita T, Kagami S, Kawagoe T, Shimajiri S and Nabeshima K: Significance of p53 expression in background endometrium in endometrial carcinoma. Virchows Arch 466: 695-702, 2015.
2. Murali R, Soslow RA and Weigelt B: Classification of endometrial carcinoma: More than two types. Lancet Oncol 15: e268-e278, 2014.
3. Sharp ZD and Bartke A: Evidence for down-regulation of phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR)-dependent translation regulatory signaling pathways in Ames dwarf mice. J Gerontol A Biol Sci Med Sci 60: 293-300, 2005.
4. Vanderstraeten A, Luyten C, Verbist G, Tuyaerts S and Amant F: Mapping the immunosuppressive environment in uterine tumors: Implications for immunotherapy. Cancer Immunol Immunother 63: 545-557, 2014.
5. Kübler K, Ayub TH, Weber SK, Zivanovic O, Abramian A, Keyver-Paik MD, Mallmann MR, Kaiser C, Serçe NB, Kuhn W and Rudlowshi C: Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma. Gynecol Oncol 135: 176-183, 2014.
6. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264, 2012.
7. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465, 2012.
8. Topalian SL, Drake CG and Pardoll DM: Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24: 207-212, 2012.
9. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454, 2012.
10. He C, Qiao H, Jiang H and Sun X: The inhibitory role of b7-h4 in antitumor immunity: Association with cancer progression and survival. Clin Dev Immunol 2011: 695834, 2011.
11. Yi KH and Chen L: Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev 229: 145-151, 2009.
12. Terness P, Kallikourdis M, Betz AG, Rabinovich GA, Saito S and Clark DA: Tolerance signaling molecules and pregnancy: IDO, galectins, and the renaissance of regulatory T cells. Am J Reprod Immunol 58: 238-254, 2007.
13. Ino K, Yoshida N, Kajiyama H, Shibata K, Yamamoto E, Kidokoro K, Takahashi N, Terauchi M, Nawa A, Nomura S, et al: Indoleamine 2, 3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 95: 1555-1561, 2006.
14. de Jong RA, Kema IP, Boerma A, Boezen HM, van der Want JJ, Gooden MJ, Hollema H and Nijman HW: Prognostic role of indoleamine 2, 3-dioxygenase in endometrial carcinoma. Gynecol Oncol 126: 474-480, 2012.
15. Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, Park HS, Lee H, Moon WS, Chung MJ, et al: Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One 8: e82870, 2013.
16. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL and Chen L: Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4: 127ra37, 2012.
17. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, et al: Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 49: 2233-2242, 2013.
18. Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, Xu H, Nayar SK, Wang TS, Sidransky D, et al: PD-L1 expression in the Merkel cell carcinoma microenvironment: Association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 1: 54-63, 2013.
19. Huang Y, Zhao Y, Ran X and Wang C: Increased expression of herpesvirus entry mediator in 1, 25-dihydroxyvitamin D3-treated mouse bone marrow-derived dendritic cells promotes the generation of CD4+CD25+Foxp3+ regulatory T cells. Mol Med Rep 9: 813-818, 2014.
20. Togno-Peirce C, Nava-Castro K, Terrazas LI and Morales-Montor J: Sex-associated expression of co-stimulatory molecules CD80, CD86, and accessory molecules, PDL-1, PDL-2 and MHC-II, in F480+ macrophages during murine cysticercosis. Biomed Res Int 2013: 570158, 2013.
21. Rozali EN, Hato SV, Robinson BW, Lake RA and Lesterhuis WJ: Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012: 656340, 2012.
22. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, et al: Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11: 2947-2953, 2005.
23. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao YS, et al: Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 15: 971-979, 2009.
24. Kojima M, Murata S, Mekata E, Takebayashi K, Jaffee EM and Tani T: Fusion protein of mutant B7-DC and Fc enhances the antitumor immune effect of GM-CSF-secreting whole-cell vaccine. J Immunother 37: 147-154, 2014.
25. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, et al: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104: 3360-3365, 2007.
26. Karim R, Jordanova ES, Piersma SJ, Kenter GG, Chen L, Boer JM, Melief CJ and van der Burg SH: Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 15: 6341-6347, 2009.
27. Cheng L, Jiang J, Gao R, Wei S, Nan F, Li S and Kong B: B7-H4 expression promotes tumorigenesis in ovarian cancer. Int J Gynecol Cancer 19: 1481-1486, 2009.
28. Chen C, Qu QX, Shen Y, Mu CY, Zhu YB, Zhang XG and Huang JA: Induced expression of B7-H4 on the surface of lung cancer cell by the tumor-associated macrophages: A potential mechanism of immune escape. Cancer Lett 317: 99-105, 2012.
29. Miyatake T, Tringler B, Liu W, Liu SH, Papkoff J, Enomoto T, Torkko KC, Dehn DL, Swisher A and Shroyer KR: B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol 106: 119-127, 2007.
30. Qian Y, Shen L, Cheng L, Wu Z and Yao H: B7-H4 expression in various tumors determined using a novel developed monoclonal antibody. Clin Exp Med 11: 163-170, 2011.
31. Cindolo L, Benvenuto G, Salvatore P, Pero R, Salvatore G, Mirone V, Prezioso D, Altieri V, Bruni CB and Chiariotti L: Galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas. Int J Cancer 84: 39-43, 1999.
32. Demydenko D and Berest I: Expression of galectin-1 in malignant tumors. Exp Oncol 31: 74-79, 2009.
33. Saussez S, Lorfevre F, Lequeux T, Laurent G, Chantrain G, Vertongen F, Toubeau G, Decaestecker C and Kiss R: The determination of the levels of circulating galectin-1 and-3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol 44: 86-93, 2008.
34. Kim MK, Sung CO, Do IG, Jeon HK, Song TJ, Park HS, Lee YY, Kim BG, Lee JW and Bae DS: Overexpression of Galectin-3 and its clinical significance in ovarian carcinoma. Int J Clin Oncol 16: 352-358, 2011.
35. van den Brûle F, Califice S, Garnier F, Fernandez PL, Berchuck A and Castronovo V: Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin. Lab Invest 83: 377-386, 2003.
36. Stewart CJ and Crook ML: Galectin-3 expression in uterine endometrioid adenocarcinoma: comparison of staining in conventional tumor glands and in areas of MELF pattern myometrial invasion. Int J Gynecol Pathol 29: 555-561, 2010.
37. van den Brule FA, Buicu C, Berchuck A, Bast RC, Deprez M, Liu FT, Cooper DN, Pieters C, Sobel ME and Castronovo V: Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol 27: 1185-1191, 1996.
38. Brustmann H, Riss D and Naudé S: Galectin-3 expression in normal, hyperplastic, and neoplastic endometrial tissues. Pathol Res Pract 199: 151-158, 2003.
39. Ege CB, Akbulut M, Zekioğlu O and Ozdemir N: Investigation of galectin-3 and heparanase in endometrioid and serous carcinomas of the endometrium and correlation with known predictors of survival. Arch Gynecol Obstet 284: 1231-1239, 2011.
40. Mylonas I, Mayr D, Walzel H, Shabani N, Dian D, Kuhn C, Kunze S, Jeschke U and Friese K: Mucin 1, Thomsen-Friedenreich expression and galectin-1 binding in endometrioid adenocarcinoma: An immunohistochemical analysis. Anticancer Res 27: 1975-1980, 2007.
41. Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D'Andrea AD, Wu CJ, et al: Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-Infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol: Jul 9, 2015 (Epub ahead of print).